By NewsDesk  @infectiousdiseasenews Johnson & Johnson’s two-dose Ebola vaccine regimen is safe, well tolerated and produces a strong immune response in people over the age of one, according to...

An immunization regimen using two Ebola vaccine candidates was safe and well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial. Results from the study are...

Bavarian Nordic A/S announced today the initiation of a Phase 1, first-in-human clinical trial of the preventative Ebola vaccine regimen consisting of MVA-BN® Filo and the AdVac® technology from Crucell...